僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用. Ixekizumab （LY2439821） is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A （KD<3 pM）. Ixekizumab directly blocks IL-17A binding to IL-17RA （IL-17A receptor） but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis